- Home
- CEV vs SERA Comparison
CEV vs SERA Comparison
Compare CEV & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- SERA
- Stock Information
- Founded
- CEV 1999
- SERA 2008
- Country
- CEV United States
- SERA United States
- Employees
- CEV N/A
- SERA N/A
- Industry
- CEV Finance/Investors Services
- SERA Precision Instruments
- Sector
- CEV Finance
- SERA Health Care
- Exchange
- CEV Nasdaq
- SERA Nasdaq
- Market Cap
- CEV 67.8M
- SERA 70.4M
- IPO Year
- CEV N/A
- SERA 2021
- Fundamental
- Price
- CEV $9.61
- SERA $2.77
- Analyst Decision
- CEV
- SERA
- Analyst Count
- CEV 0
- SERA 0
- Target Price
- CEV N/A
- SERA N/A
- AVG Volume (30 Days)
- CEV 19.6K
- SERA 763.6K
- Earning Date
- CEV 01-01-0001
- SERA 08-06-2025
- Dividend Yield
- CEV 4.23%
- SERA N/A
- EPS Growth
- CEV N/A
- SERA N/A
- EPS
- CEV 0.36
- SERA N/A
- Revenue
- CEV N/A
- SERA $115,000.00
- Revenue This Year
- CEV N/A
- SERA $390.13
- Revenue Next Year
- CEV N/A
- SERA $440.54
- P/E Ratio
- CEV $29.36
- SERA N/A
- Revenue Growth
- CEV N/A
- SERA N/A
- 52 Week Low
- CEV $8.83
- SERA $1.37
- 52 Week High
- CEV $10.91
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- CEV 58.66
- SERA 55.77
- Support Level
- CEV $9.64
- SERA $2.34
- Resistance Level
- CEV $9.78
- SERA $2.80
- Average True Range (ATR)
- CEV 0.07
- SERA 0.37
- MACD
- CEV 0.01
- SERA 0.05
- Stochastic Oscillator
- CEV 75.00
- SERA 37.00
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.